HCW Biologics Faces Delisting Concerns
Ticker: HCWB · Form: 8-K · Filed: Feb 7, 2025 · CIK: 1828673
Sentiment: bearish
Topics: delisting, listing-standards, regulatory
TL;DR
HCW Biologics might get delisted, filing an 8-K about it.
AI Summary
HCW Biologics Inc. filed an 8-K on February 7, 2025, reporting a notice of delisting or failure to satisfy continued listing rules. The company is also reporting other events and filing financial statements and exhibits related to this situation.
Why It Matters
This filing indicates potential issues with HCW Biologics' continued listing on an exchange, which could significantly impact its stock trading and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting directly threatens the company's ability to remain publicly traded, posing a significant risk to investors.
Key Players & Entities
- HCW Biologics Inc. (company) — Registrant
- February 05, 2025 (date) — Earliest event reported
- February 7, 2025 (date) — Filing date
- 2929 N. Commerce Parkway, Miramar, Florida 33025 (location) — Principal Executive Offices
FAQ
What specific listing rule or standard has HCW Biologics Inc. failed to satisfy?
The filing does not specify the exact rule or standard that HCW Biologics Inc. has failed to satisfy, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is February 05, 2025.
What is the Commission File Number for HCW Biologics Inc.?
The Commission File Number for HCW Biologics Inc. is 001-40591.
What is the business address of HCW Biologics Inc.?
The business address of HCW Biologics Inc. is 2929 N. Commerce Parkway, Miramar, Florida 33025.
What are the main items reported in this 8-K filing?
This 8-K filing reports a Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard, Other Events, and Financial Statements and Exhibits.
Filing Stats: 931 words · 4 min read · ~3 pages · Grade level 13.5 · Accepted 2025-02-07 16:45:08
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share HCWB The Nasdaq Stock Mar
- $1 — did not maintain a minimum bid price of $1 per share, in accordance with Nasdaq Li
- $15,000,000 M — d securities ("MVPHS") closed below the $15,000,000 MVPHS threshold required for continued li
- $50,000,000 M — ed securities ("MVLS") closed below the $50,000,000 MVLS threshold required for continued lis
Filing Documents
- hcwb-20250205.htm (8-K) — 45KB
- 0000950170-25-016390.txt ( ) — 157KB
- hcwb-20250205.xsd (EX-101.SCH) — 24KB
- hcwb-20250205_htm.xml (XML) — 5KB
01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed, on August 12, 2024, HCW Biologics Inc. (the "Company") received written notices from the Listing Qualifications Staff ("Staff") of the Nasdaq Stock Market LLC ("Nasdaq") which notified the Company that, for the 30 consecutive business days ended August 6, 2024, the Company's security did not maintain a minimum bid price of $1 per share, in accordance with Nasdaq Listing Rule 5810(c)(3)(A) ("Bid Price Rule"). Also on August 12, 2024, the Company received written notification from the Staff that for the 30 consecutive business days ended August 8, 2024, the Company's market value of publicly held securities ("MVPHS") closed below the $15,000,000 MVPHS threshold required for continued listing on the Nasdaq Global Market under Nasdaq Listing Rule 5450(b)(2)C) (the "MVPHS Rule"). The Company was granted a compliance period of 180 calendar days from the date of the notice ("Compliance Period") for these delinquencies, in accordance with Nasdaq Listing Rule 5810(c)(3)(A) for the Bid Price Rule and Nasdaq Listing Rule 5450(b)(2)C) for the MVPHS Rule. The Company did not regain compliance with the Bid Price Rule by February 3, 2025 or the MVPHS Rule by February 4, 2025. Accordingly, by letter dated February 5, 2025, the Staff notified the Company that its securities were subject to delisting from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearing Panel (the "Panel"). As previously disclosed on December 23, 2024, the Company received written notice from the Staff regarding for the 30 consecutive business days ended June 17, 2024, the Company's market value of listed securities ("MVLS") closed below the $50,000,000 MVLS threshold required for continued listing on the Nasdaq Global Market under Nasdaq Listing Rule 5450(b)(3)(A) (the "MVLS Rule"). The Company was granted a request for a hearing before the Nasdaq
01 Other Events
Item 8.01 Other Events. As previously disclosed in the Company's Form 8-K filed on December 23, 2024, pursuant to applicable Nasdaq Rules, the Company issued a press release on December 23, 2024 announcing receipt of a Nasdaq Staff determination letter, for noncompliance with the MVLS Rule for Nasdaq Global Market tier, as required, with a description of each specific basis and concern identified by Nasdaq in that letter.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HCW BIOLOGICS INC. Date: February 7, 2025 By: /s/ Hing C. Wong Hing C. Wong, Founder and Chief Executive Officer